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ABSTRACT
Background: This study was conducted to evaluate the role of some serum oxidative stress biomarkers 
for breast cancer diagnosis, incidence and monitoring the effects of surgery and chemotherapy. 
Methods: A total of 35 breast cancer patients (before surgery, after two weeks of surgery and after 6 cy-
cles of chemotherapy) and 35 normal healthy controls were analyzed for serum oxidative stress markers 
including total antioxidant capacity (TAC), malondialdehyde (MDA), total, reduced (GSH) and oxidized 
(GSSG) glutathione and glutathione redox status (GSH/GSSG). 
Results: The serum levels of MDA and GSSG were significantly higher in breast cancer patients than 
controls. The serum levels of GSH, TAC and GSH/GSSG ratio were significantly lower in breast cancer 
patients than controls. After surgery, the serum levels of MDA and GSSG were significantly decreased, 
while the serum levels of GSH were significantly increased, compared with their levels before surgery. Six 
cycles of chemotherapy showed the non-significant effect on the serum levels of the assayed biomarkers. 
ROC curve analysis demonstrated that MDA and GSH were superior to the GSH/GSSG ratio, TAC and 
GSSG. Increased levels of MDA and GSSG and reduced levels of GSH, TAC and GSH/GSSG ratio were 
found to significantly increase the risk of breast cancer. 
Conclusions: All of the assayed biomarkers can be used for prediction of breast cancer with MDA and 
GSH being superior to the others. MDA, GSH and GSSG were able to monitor the effect of surgery. All 
of the assayed biomarkers were found to be associated with breast cancer risk. None of the assayed 
biomarkers was able to predict the effect of chemotherapy. 
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Introduction 
Reactive oxygen species (ROS) such as superoxide 
radical, hydroxyl radical, and hydrogen peroxide are 
metabolic by-products leaking from the complexes I and 
III of the mitochondrial respiratory chain [1]. Oxidative 
stress is considered to be involved in the pathophysiol-
ogy of all cancers including breast cancer [2, 3].
Breast cancer cells are subjected to a high level 
of oxidative stress, both intracellular and extracellular. 
To ensure survival, cancer cells must acquire special 
adaptive mechanisms that counteract the toxic effects 
of free radicals exposure. These mechanisms may 
involve the activation of redox-sensitive transcription 
factors and the increased expression of antioxidant 
enzymes and antiapoptotic proteins. Moreover, it was 
revealed that different breast cancer cell types show 
different intracellular antioxidant capacities that may 
determine their ability to resist radiotherapy and che-
motherapy [4]. 
The involvement of oxidative stress in breast car-
cinogenesis has not been extensively documented 
[5]. Panis et al. [6] reported that although a growing 
number of studies have focused on the relationship 
between breast cancer and oxidative stress, none of 
the previous reports determined the impact of the sys-
temic oxidative stress status on patients with primary 
breast tumours, as well as if its removal could change 
the oxidative profiling of plasma. 
One of the possible clinical applications of oxidative 
stress status in cancer is the use of oxidative stress 
markers as tumour markers [7]. The current study ex-
amined the extent of lipid peroxidation, total antioxidant 
capacity and the status of glutathione in serum of breast 
cancer patients to investigate the role of these biomark-
ers in the etiology, prediction, risk and monitoring the 
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effects of surgery and chemotherapy on breast cancer 
patients in an attempt to improve the clinical outcome 
of those patients. 
Subjects and methods
Seventy females were enrolled in this case-control 
study. Females were divided into two groups. Group 
I (breast cancer patients group) which included 35 fe-
male patients with breast invasive ductal carcinoma 
of clinical stages II and III [8] (recently detected, not 
underwent surgery or receiving chemotherapy). Their 
mean age was 43.73 ± 12.2 years. Patients were recruit-
ed from the Department of Experimental and Clinical 
Surgery of the Medical Research Institute, Alexandria 
University, Egypt in the period from January 2018 till 
June 2018. Group II (normal healthy control group): 
It included 35 apparently normal healthy female volun-
teers of comparable age (42.18 ± 11.05), menstrual 
cycle and socioeconomic status as patients.
After having approval from the ethics committee, 
Medical Research Institute, Alexandria University, 
Egypt, signed informed consents were obtained from 
all subjects who agreed to participate in this study. 
Each patient underwent full history recording, thorough 
clinical examination, routine laboratory investigations 
including complete blood count (CBC), mammography 
of breast and ultrasonography of abdomen and liver, 
radiological investigations including X-ray chest, CT 
scan and bone scan when needed and fine needle 
aspiration cytology (FNAC) of breast mass to establish 
the pathological diagnosis in the patients. 
The clinicopathologic data were obtained from 
patients’ pathology reports. The collected data includ-
ed tumour size, tumour pathological grade, axillary 
lymph node involvement, vascular invasion and status 
of estrogen receptor (ER) and progesterone receptor 
(PR). Each breast cancer patient’s clinical stage was 
determined by the oncologist according to the tu-
mour-nodes-metastasis (TNM) classification system [8]. 
All 35 breast cancer patients were subjected to 
modified radical mastectomy (MRM) surgery [9]. The 
patients received adjuvant combination chemotherapy 
[5-Fluorouracil, Adriamycin and Cyclophosphamide 
(FAC)] [10] for 6 cycles. After 6 cycles of chemothera-
py, breast cancer patients were re-evaluated clinically, 
laboratory and radiologically to evaluate the clinical 
response. 
Laboratory Investigations
Five-milliliter blood sample was collected once 
from normal healthy female volunteers and from breast 
cancer patients before surgery, after 2 weeks of surgery 
and after 6 cycles of chemotherapy. Immediately after 
withdrawing, blood samples were allowed to coagu-
late and centrifuged for 20 minutes at 3500 rpm. The 
separated serum samples were aliquoted, frozen at 
-80 °C, and stored until assayed. After thawing, each
serum aliquot was assayed only once. Determination
of serum levels of MDA, total antioxidant capacity, total
and reduced forms of glutathione were carried out at
Radiation Sciences Department, Medical Research
Institute, Alexandria University, Egypt. While the serum
levels of oxidized glutathione and glutathione redox
status were estimated mathematically.
Determination of serum malondialdehyde 
concentration
Malondialdehyde (MDA) is the end product of lipid 
peroxidation. MDA was assayed using a ready-for-use 
colourimetric kit (Biodiagnostic, Egypt). MDA was 
quantified by its reaction with the exogenously added 
thiobarbituric acid (TBA) that reacts with MDA in acidic 
medium at a temperature of 95°C for 30 min to form 
thiobarbituric acid (TBA) reactive product. The absor-
bance of the resultant pink product was measured at 
534 nm. The absorbance of each serum sample was 
read against a blank (which contained only TBA) and 
a standard (which contained MDA of conc. 10 nmo-
le/ml). In each serum sample, the concentration of MDA 
was calculated according to the equation:
MDA (nmole/ml) = (Abs of serum/ 
/Abs of standard)*10
Determination of serum total antioxidant capacity
The degree of oxidative stress was assessed by de-
termining total antioxidant activity using a ready-for-use 
colourimetric kit (Biodiagnostic, Egypt). The principle of 
the method depends on the reaction of antioxidants in 
the sample with a defined amount of exogenously added 
H2O2. The antioxidants in the sample eliminate a certain 
amount of the added hydrogen peroxide. The residual 
H2O2 is determined colourimetrically by an enzymatic reac-
tion involving the conversion of the exogenously added 3, 
5, dichloro-2-hydroxyl benzenesulfonate to a pink coloured 
product. The absorbance of each sample was read at 
505 nm against a blank in which the sample was replaced 
with distilled water. In each sample, the total antioxidant 
concentration was calculated according to the equation: 
Total antioxidant concentration (mM/L) 
= (Abs of blank-Abs of sample)*3.33
Determination of serum levels of total glutathione
The enzymatic method described by Griffith [11]
was used to measure the levels of total glutathione. 
This is a sensitive and specific enzymatic method which 
depends on the oxidation of reduced glutathione (GSH) 
Taha I. Hewala, Moustafa R. Abo Elsoud, Oxidative stress biomarkers in breast cancer
3www.journals.viamedica.pl/medical_research_journal
by 5,5-dithiobis-2-nitrobenzoic acid (DTNB) to yield 
oxidized glutathione (GSSG) and 5-thio-2-nitrobenzoic 
acid (TNB). Oxidized GSSG is reduced enzymatically 
by the action of glutathione reductase and NADPH to 
regenerate GSH which reacts again. The rate of TNB 
formation is monitored at 340 nm and is proportional 
to the sum of GSH and GSSG present in the sample.
Total glutathione (U/L) = 4019 x D 340 nm/min
Determination of serum levels of reduced 
glutathione (GSH)
The level of reduced glutathione in serum was 
assessed using a ready-for-use colourimetric kit (Biodi-
agnostic, Egypt). The method is based on the reduction 
of 5,5` dithiobis -2-nitrobenzoic acid (DTNB ) by glutathi-
one (GSH) to produce a yellow compound. The reduced 
chromogen directly proportional to GSH concentration 
and its absorbance can be measured at 405 nm. 
Serum level of GSH(mg/dl) 
= (A"sample" )*66.66
Estimation of serum levels of oxidized glutathione 
(GSSG):
Oxidized glutathione (GSSG) was obtained by 
subtracting the values of reduced glutathione (GSH) 
from the values of total glutathione (tGSH) [12].
GSSG = tGSH — GSH
Estimation of serum glutathione redox status 
(GSH/GSSG)
The most widely used indicator of the glutathione 
redox status (GSH/GSSG) of the cells is according to 
Kirlin et al. [13]: 
Redox Status = (Serum level of GSH)/ 
/(Serum level of GSSG)
Where [GSH] and [GSSG] are molar concentration 
of reduced and oxidized glutathione; respectively.
Statistical Analysis
The statistical analyses were carried out using the 
Predictive Analytics software (PASW statistics 18). The 
Non-parametric Mann-Whitney U-test was used for 
studying differences between breast cancer patients 
group and control group regarding serum levels of total 
antioxidant capacity (TAC), malondialdehyde (MDA), 
total, reduced (GSH) and oxidized (GSSG) glutathione 
and glutathione redox status (GSH/GSSG). The diag-
nostic values of assayed parameters were compared 
using the Receiver Operating Characteristic (ROC) 
curve analysis. The cut-off point for each biomarker 
was determined according to the best discrimination 
between patients and controls regarding optimal val-
ues of sensitivity and specificity using the ROC curve. 
Spearman correlation was carried out to explore the 
possible correlation between different biomarkers and 
clinicopathological data. Odd’s ratio with a 95% confi-
dence interval (95% CI) was calculated using the same 
program. P-values < 0.05 were accepted as significant.
Results
Serum levels of oxidative stress biomarkers in the 
controls and breast cancer patients before surgery, 
after two weeks of surgery and after 6 cycles of che-
motherapy.
Table 1 showed oxidative stress biomarkers in se-
rum of normal healthy control females and breast cancer 
females before surgery, after two weeks of surgery 
and after six cycles of chemotherapy. Serum levels of 
MDA and GSSG were significantly elevated in breast 
cancer patients group before surgery compared with 
Table 1. Serum levels (Mean ± SE) of oxidative stress biomarkers in the controls and breast cancer patients before 
surgery, after 2weeks of surgery and after 6 cycles of chemotherapy
Serum biomarkers Control group
(n = 35)
Breast cancer patients group
(n = 35)
BS 2 W 6 C
MDA
(nmole/ml)
11.10 ± 0.44 20.01 ± 0.37a 12.27 ± 0.29b 13.56 ± 0.33
TAC (mM/l) 1.26 ± 0.49 0.78 ± 0.46 a 0.90 ± 0.40 a 0.83 ± 0.38 a
GSSG(mg/dl) 9.23 ± 0.21 10.39 ± 2.22 a 9.64 ± 2.91 b 10.29 ± 2.98
GSH (mg/dl) 21.71 ± 1.07 15.85 ± 1.08 a 17.14 ± 2.13 a,b 13.61 ± 4.01 a
Glutathione Redox status 
(GSH/GSSG)
2.38 ± 0.47 1.84 ± 0.14 a 1.57 ± 0.16 a 1.54 ± 0.13 a
N — sample size; BS — before surgery; 2W — after two weeks of surgery; 6C — after six cycles of chemotherapy; a — significance compared 
with control group; b — significance compared with breast cancer group before surgery; c — significance compared with breast cancer group 
after two weeks of surgery; significance was considered at p-value < 0.05.
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Figure 1. The ROC curve analysis of the assayed biomarkers for prediction of breast cancer
Table 2. The ROC curve-based characteristics for assayed serum markers in breast cancer patients before surgery
Variables The area under 
the curve (%)
P-value Cut-off value Sensitivity
%
Specificity
%
MDA
(nmol/ml)
96.0 0.001* 13.81 90 80
TAC
(mM/l)
76.9 0.005* 0.90 85.7 57.7
GSSG
(mg/ml)
70.5 0.035* 9.9 84.6 80.6
GSH
(mg/ml)
92.9 0.000* 17.30 92.9 100
Glutathione Redox 
status GSH/GSSG))
82.1 0.001* 1.70 92.9 76.9
*Significance was considered at p-value < 0.05.
the control group. The serum levels of MDA and GSSG 
were significantly decreased in breast cancer patients 
group after two weeks of surgery compared with their 
levels before surgery. A non-significant difference was 
found in serum levels of MDA and GSSG after 6 cycles 
of chemotherapy compared with their levels after two 
weeks of surgery. 
Table 1 also showed that serum levels of TAC, 
GSH and glutathione redox status (GSH/GSSG) were 
significantly decreased in breast cancer females before 
surgery compared with the control group. The serum 
levels of reduced glutathione in breast cancer patients 
group after two weeks of surgery were significantly 
elevated compared with their levels before surgery. 
After six cycles of chemotherapy, none of these bio-
markers significantly differed from its level after two 
weeks of surgery.
Comparison between serum levels 
of oxidative stress biomarkers as 
diagnostic markers in breast cancer 
patients using the Receiver Operating 
Characteristic (ROC) curve analysis
As shown in Table 2 and Figure 1, the ROC curve 
analysis was used in the present study to compare the 
diagnostic values of serum oxidative stress biomarkers 
depending on the area under the ROC curve (AUC). 
The higher AUC corresponds to a better diagnostic 
test. Serum levels of MDA showed a significant AUC 
(96%),(p = 0.001), with sensitivity (90%) and specificity 
(80%) at a cut-off value (13.81 nmol/ml). Serum levels of 
TAC showed a significant AUC (76.9%),(p = 0.005), with 
sensitivity (85.7%) and specificity (57.7%) at a cut-off 
value (0.90 mM/L). Serum levels of oxidized glutathi-
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Table 3. The association of serum assayed biomarkers with the risk of breast cancer incidence
Assayed Biomarker breast cancer 
group
(n = 35)
control group
(n = 35)
Odds ratio 
(OR)
95% CI p-value
MDA
(nmole/ml)
 < 13.81 ® 13 30 10.15 1.69–11.06 P = 0.002 *
≥ 13.81 22 5
TAC
(mM/l)
 ≥ 0.9 ® 5 20 8.00 2.51–25.51 P = 0.0004*
< 0.9 30 15
GSSG
(mg/ml)
< 9.9® 5 28 24 6.82–84.43 P = 0.0011*
≥ 9.9 30 7
GSH
(mg/ml)
≥ 17.30® 0 27 22.97 12.70–41.55 P = 0.0002*
< 17.30 35 8
Glutathione redox status 
(GSH/GSSG)
≥ 1.70 ® 2 32 17.60 7.56–23.11 P = 0.0001*
< 1.70 33 3
n — Sample size; ® — reference group; CI — Confidence interval;* — Significance was considered at P-value < 0.05
one showed a significant AUC (70.5),(p = 0.035), with 
sensitivity (84.6%) and specificity (80.6%) at a cut-off 
value (9.9 mg/dl). Serum levels of reduced glutathione 
showed a significant AUC (92.9),(p = 0.000), with 
sensitivity (92.9%) and specificity (100%) at a cut-off 
value (17.3 mg/dl). Serum levels of glutathione redox 
status (GSH/GSSG) showed a significant AUC (82.1), 
(p = 0.001), with sensitivity (92.9%) and specificity 
(76.9%) at a cut-off value (1.70). 
The association of serum levels of 
oxidative stress biomarkers with the 
risk of breast cancer incidence
The values of odds ratio and confidence interval at 
certain cut-off values for serum levels of oxidative stress 
biomarkers were shown in Table 3.
Correlation of serum levels of oxidative 
stress biomarkers with breast cancer 
clinicopathological data 
The results of the current study showed that none 
of the assayed biomarkers had a significant correlation 
with anyone of breast cancer clinicopathological fea-
tures.
Discussion
Oxygen-free radicals (OFR), generated by a number 
of processes in vivo, are highly reactive and toxic [14]. 
However, biological systems have evolved an array 
of enzymatic and non-enzymatic antioxidant defence 
mechanisms to combat the deleterious effects of OFR. 
Reduced glutathione (GSH), in conjunction with gluta-
thione peroxidase (GPx) and glutathione S-transferase 
(GST), plays a central role in the defence against free 
radicals, peroxides and a wide range of xenobiotics and 
carcinogens [15, 16]. 
Oxidative stress arises when there is an imbalance 
between OFR formation and scavenging by antioxi-
dants. Excessive production of OFR can cause oxidative 
damage to biomolecules resulting in lipid peroxidation, 
mutagenesis and carcinogenesis. OFR-induced lipid 
peroxidation has been implicated in neoplastic trans-
formation. Damage to the breast epithelium by OFR can 
lead to fibroblast proliferation, epithelial hyperplasia, 
cellular atypia and breast cancer [17]. 
In the current study, the serum levels of MDA were 
found to be significantly elevated in breast cancer pa-
tients than controls. As MDA is considered a marker for 
lipid peroxidation, this means that lipid peroxidation may 
play a role in breast carcinogenesis. Our results were 
in agreement with Rajneesh et al.,2008 [17].
Regarding the effect of MRM on the serum levels of 
MDA, the current study revealed significantly decreased 
levels of MDA after two weeks of surgery compared 
with its levels before surgery; this means that serum 
MDA can be used as an indicator for the effect of MRM 
on breast cancer patients. With respect to the effect of 
chemotherapy on the serum levels of MDA, our results 
showed a non-significant increase in serum MDA levels 
after 6 cycles of adjuvant combination chemotherapy 
compared with its levels after 2 weeks of surgery. 
Total antioxidant capacity (TAC) measures the per-
oxyl-scavenging capacity of the extracellular antioxidant 
system that is comprised of sulphydryl groups, urate, 
ascorbate, carotenoids, retinol, a-tocopherol, bilirubin 
and proteins. TAC reflects residual antioxidant capacity 
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after the consumption of reactive oxygen species [18, 
19]. In the current study, the serum levels of TAC were 
found to be significantly reduced in breast cancer patients 
before surgery than controls, this means that TAC may 
have a protective role against breast carcinogenesis. Our 
results supported those of Mahmood et al., 2009 [20] 
On the other hand, neither MRM nor chemotherapy has 
a significant effect on the serum levels of TAC.
Regarding the serum levels of GSH, the results of 
the current study showed significantly declined levels 
of GSH in breast cancer patients compared with normal 
healthy controls. This means that serum GSH can be 
used to differentiate breast cancer patients from con-
trols. The results of the current study were in agreement 
with the findings of Yeh et al. [21] who reported that the 
levels of GSH were significantly decreased in the blood 
of breast cancer patients compared with controls. Yeh 
et al. [21] suggested that this could be due to both the 
increased GSH detoxification capacities, which can 
lead to GSH depletion within the red blood cells, and 
lower efficacy in the reduction of GSSG to GSH. These 
findings support the idea of the protective role of GSH 
against reactive oxygen species-mediated oxidative 
stress in cancer patients. At the same time, Yeh et al. 
[21] proposed that GSH should be regarded as an
important biomarker for detecting breast malignancy.
With respect to the effect of surgery on serum levels 
of GSH, the results of the current study showed that 
the serum levels of GSH were significantly increased 
in breast cancer patients after two weeks of MRM com-
pared with their levels before surgery. This means that 
the serum levels of GSH can be used to monitor the 
effect of MRM on breast cancer patients. The findings of 
the current study can be explained according to Navarro 
et al. [22] who suggested that the tumour mass acts as 
a source for peroxides that reacts with and consume 
GSH leading to depletion of GSH. On this base, removal 
of the tumour decreases these peroxides resulting in an 
increase in GSH content which is in agreement with the 
results of the current study. With reference to the effect 
of six cycles of chemotherapy, the results of the current 
study showed a non-significant effect of chemotherapy 
on the serum levels of GSH compared with their levels 
after two weeks of MRM. This means that GSH cannot 
be used to monitor the response of breast cancer pa-
tients to chemotherapy.
Regarding the serum levels of GSSG and the glu-
tathione redox status (GSH/GSSG), the results of the 
current study indicated significantly elevated levels of 
GSSG and significantly decreased levels of glutathione 
redox status (GSH/GSSG) in the serum of breast cancer 
patients than controls. These findings were in accor-
dance with the results of Navarro et al. [22] who reported 
significantly higher levels of GSSG and decreased lev-
els of glutathione redox status (GSH/GSSG) in breast 
cancer patients compared with controls. In their study, 
Navarro et al. [22] postulated that during cancer growth, 
the glutathione redox status (GSH/GSSG) decreases 
in the blood due to an increase in GSSG levels. Two 
reasons may explain the increase in blood GSSG: (a) 
the increase in peroxide production by the tumour that 
can lead to GSH oxidation within the red blood cells; 
and (b) an increase of GSSG release from different 
tissues into the blood.
With respect to the effect of surgery on the se-
rum levels of GSSG and glutathione redox status 
(GSH/GSSG), the results of the current study showed 
that the serum levels of GSSG were significantly de-
creased, with no significant effect on glutathione redox 
status (GSH/GSSG), in breast cancer patients after 
two weeks of MRM compared with their levels before 
surgery. This means that the serum levels of GSSG 
can be used to monitor the effect of MRM on breast 
cancer patients. The findings of the current study can 
be also explained according to Navarro et al. [22] who 
suggested that the tumour mass acts as a source for 
peroxides that reacts with GSH resulting in the for-
mation of GSSG. When the tumour mass is removed 
the amount of these peroxides decreases resulting in 
a decrease in the amount of GSSG formed due to the 
detoxification reaction. With reference to the effect of 
six cycles of chemotherapy, the results of the current 
study showed non-significant effects of chemotherapy 
on the serum levels of GSSG and glutathione redox 
status (GSH/GSSG) compared with their levels after 
two weeks of MRM. This means that none of these 
biomarkers can be used to monitor the response of 
breast cancer patients to chemotherapy.
The significant elevation in the serum levels of 
MDA and GSSG and the significant decline in the 
serum level of TAC, GSH and glutathione redox status 
(GSH/GSSG) in breast cancer patients before surgery 
compared to normal controls suggested the possibility 
of using anyone of these biomarkers for prediction of 
breast cancer to differentiate the breast cancer patient 
from the normal healthy controls. This directed us to 
compare the diagnostic accuracy of these biomarkers 
to determine which of them has the highest and the 
lowest diagnostic value. This comparison was carried 
out using the ROC curve analysis in such a way that the 
greater area under the ROC curve corresponds to a bet-
ter diagnostic test. Serum levels of MDA showed the 
greatest significant area under the curve (96%) followed 
by GSH (92.9%), glutathione redox status (GSH/GSSG) 
(82.1%), TAC (76.9%) then GSSG (70.5%). These re-
sults suggested that serum levels of MDA are superior 
to GSH, GSH/GSSG, TAC and GSSG for diagnosis 
of breast cancer patients. The results of the current 
study supported those reported by Pande et al. [23] 
who found that the diagnostic accuracy of serum MDA 
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was superior to TAC for distinguishing breast cancer 
patients from controls
Regarding the association of the assayed biomark-
ers with the risk of breast carcinogenesis, the results 
of the current study illustrated that increased levels of 
serum MDA and GSSG and decreased levels of TAC, 
GSH and glutathione redox status can significantly 
potentiate breast cells for malignancy. Pande at al., 
2012 [23].
From the current study, it could be concluded that 
all of the assayed biomarkers have a diagnostic role in 
breast cancer patients with MDA and GSH being supe-
rior to the other biomarkers for discrimination of breast 
cancer patients from controls. Serum levels of MDA, 
GSH and GSSG were good indicators for monitoring 
the effect of surgery. All the assayed biomarkers were 
found to be associated with breast cancer risk. None 
of the assayed biomarkers could predict the effect of 
chemotherapy. 
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